PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.

Animals Breast Neoplasms / drug therapy Female Humans Immunoconjugates / pharmacology Lung Neoplasms / drug therapy Mice Mice, Nude Stomach Neoplasms / drug therapy

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
10 2020
Historique:
received: 26 03 2020
revised: 04 06 2020
accepted: 14 07 2020
pubmed: 5 8 2020
medline: 7 8 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

The approval of ado-trastuzumab emtansine (T-DM1) in HER2

Identifiants

DOI: 10.1158/1535-7163.MCT-20-0237 PMID: 32747418
pubmed: 32747418
pii: 1535-7163.MCT-20-0237
doi: 10.1158/1535-7163.MCT-20-0237
doi:

Substances chimiques

Immunoconjugates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2068-2078

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Edmund I Graziani (EI)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.
ORCID: 0000-0003-4742-3900

Matthew Sung (M)

Pfizer Inc., Oncology Research & Development, Pearl River, New York. sungms@gmail.com Psapra111@gmail.com.

Dangshe Ma (D)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Bitha Narayanan (B)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Kimberly Marquette (K)

Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts.

Sujiet Puthenveetil (S)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.
ORCID: 0000-0001-9005-8422

L Nathan Tumey (LN)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.
ORCID: 0000-0001-8890-7018

Jack Bikker (J)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.

Jeffrey Casavant (J)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.

Eric M Bennett (EM)

Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts.

Manoj B Charati (MB)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Jonathon Golas (J)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Christine Hosselet (C)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Cynthia M Rohde (CM)

Pfizer Inc., Drug Safety Research & Development, Pearl River, New York.

George Hu (G)

Pfizer Inc., Drug Safety Research & Development, Pearl River, New York.

Magali Guffroy (M)

Pfizer Inc., Drug Safety Research & Development, Pearl River, New York.

Hadi Falahatpisheh (H)

Pfizer Inc., Drug Safety Research & Development, Pearl River, New York.

Martin Finkelstein (M)

Pfizer Inc., Drug Safety Research & Development, Pearl River, New York.

Tracey Clark (T)

Pfizer Inc., BioMedicine Design, Groton, Connecticut.

Frank Barletta (F)

Pfizer Inc., BioMedicine Design, Pearl River, New York.

Lioudmila Tchistiakova (L)

Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts.

Judy Lucas (J)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Edward Rosfjord (E)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.
ORCID: 0000-0002-3449-7444

Frank Loganzo (F)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.
ORCID: 0000-0002-2976-8502

Christopher J O'Donnell (CJ)

Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut.
ORCID: 0000-0003-1004-7139

Hans-Peter Gerber (HP)

Pfizer Inc., Oncology Research & Development, Pearl River, New York.

Puja Sapra (P)

Pfizer Inc., Oncology Research & Development, Pearl River, New York. sungms@gmail.com Psapra111@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › PF-06804103, A Site-specific Anti-HER2...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › PF-06804103, A Site-specific Anti-HER2...